

https://dspace.org/

Clostridioides difficile infection and testing rates in South Africa A multicentre study 20172020

Trusha Nana; P Ramjathan; K Han; K Reddy

ELSEVIER SCI LTD
https://hdl.handle.net/10539/45607
WOS

Downloaded from a DSpace repository. https://dspace.org/

Anaerobe 91 (2025) 102937

Contents lists available at ScienceDirect

Anaerobe

journal homepage: www.elsevier.com/locate/anaerobe

Clostridioides difficile (including epidemiology)

Clostridioides difficile infection and testing rates in South Africa: A multicentre study, 2017–2020

Trusha Nana [a,b,*], Praksha Ramjathan [c,d], Khine Swe-Swe Han [c,d], Kessendri Reddy [e,f]

[a] Department of Clinical Microbiology, Faculty of Health Sciences, University of Witwatersrand, 7 York Road, Parktown, Gauteng, 2193, South Africa
[b] National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa
[c] Department of Medical Microbiology, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Mazisi Kunene Road, Glenwood, Durban, KwaZulu-Natal, 4001, South Africa
[d] National Health Laboratory Service, Inkosi Albert Luthuli Central Hospital, Durban, KwaZulu-Natal, South Africa
[e] Division of Medical Microbiology and Immunology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zilj Drive, Parow, Cape Town, Western Cape, 7505, South Africa
[f] National Health Laboratory Service, Tygerberg, Western Cape, South Africa

ARTICLE INFO

Handling Editor: Daniel Knight

Keywords:
Clostridioides difficile infection
Clostridioides difficile testing rate
Clostridioides difficile epidemiology
Africa
recurrent CDI Africa

ABSTRACT

Objectives: To describe *Clostridioides difficile* infection (CDI) rates and testing practices, at three tertiary/quaternary hospitals in South Africa (SA) for the period 2017 to 2020.
Methods: A retrospective laboratory record review of all *C. difficile* testing at the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), Tygerberg Hospital (TBH) and Inkosi Albert Luthuli Central Academic Hospital (IALCH) was performed. Clinical records of patients with rCDI were reviewed to determine recurrent CDI (rCDI) rates.
Results: The median primary CDI rates per 10 000 patient-days (PD) were 5.3 at CMJAH, 1.8 at TBH, and 0.3 at IALCH. In 2020, all hospitals reported an increase in primary CDI rates compared to 2019. The median testing rates per 10 000 PD were 39 at CMJAH, 14 at TBH, and 4 at IALCH. The median age of patients with primary CDI was 33 years (IQR: 22–45 years). The rCDI rates ranged from 2 to 5 per 100 incident episodes.
Conclusion: Significant variations in CDI and testing rates were observed across the three hospitals. An increase in CDI rates was noted at all centres during the 2020 SARS-CoV-2 outbreak. Advanced age was not prevalent in the cohort, and rCDI rates were relatively low. These findings highlight the need for systematic surveillance of healthcare-onset CDI across SA hospitals.

1. Introduction

Clostridioides difficile infections (CDI) are among the leading healthcare-associated infections worldwide and are associated with significant morbidity and mortality [1,2]. Certain risk factors predisposing patients to the development of CDI are well-established [1]. In South Africa (SA), risk factors associated with CDI include documented tuberculosis (TB) infection (including multidrug-resistant TB), hospitalisation prior to current admission [2], and antimicrobial exposure [2,3]. The relationship between TB and CDI is further emphasised by the high incidence of CDI in specialised TB hospitals [4]. Antimicrobial consumption in SA is also substantial and the use of broad-spectrum agents is common [5]. Although an association between CDI and low CD4 counts in HIV-infected individuals has been suggested [2], there is currently a lack of data particularly from the SA context, which houses the largest antiretroviral programme in the world, to support this [2,6].

CDI is a notifiable medical condition in SA, but co-ordinated surveillance of CDI is not practiced and the burden of disease is likely underestimated due to a lack of awareness and limited access to laboratory diagnostics in some settings [7–9]. A national assessment of the burden of CDI over a one-year period in 2016/2017 revealed a test positivity rate of 18.5 %. The national incidence rate was 53.89/100 000 admissions and was highest in the Gauteng province followed by the Western Cape. Testing rate, positivity rate and incidence varied widely

* Corresponding author. Department of Clinical Microbiology, Faculty of Health Sciences, University of Witwatersrand, 7 York Road, Parktown, Johannesburg, 2193, South Africa.
E-mail addresses: trusha.nana@nhls.ac.za (T. Nana), praksha.ramjathan@gmail.com (P. Ramjathan), Sweswe-han@ukzn.ac.za (K. Swe-Swe Han), kreddy@sun.ac.za (K. Reddy).

https://doi.org/10.1016/j.anaerobe.2024.102937
Received 19 November 2024; Received in revised form 13 December 2024; Accepted 15 December 2024
Available online 20 December 2024
1075-9964/© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

between provinces and levels of care, with specialised TB hospitals bearing the highest burden, followed by quaternary level facilities [4].

Recurrent CDI (rCDI), a complication occurring in up to 40 % of patients, is associated with even higher morbidity [10], is challenging to manage and is resource-intensive for the healthcare system [10,11]. Treatment options recommended for rCDI, like fidaxomicin and faecal microbiota transplant, are costly and often not accessible in resource-constrained settings [12]. The entity of rCDI in Africa is poorly described [6]. In SA, low rates of rCDI have been recorded (2.14 %) [4], but data are limited.

CDI is not well-understood in SA, despite the high associated morbidity and mortality [11], its emerging association with TB [2], its propensity to cause outbreaks [13,14] and the challenges associated with its treatment [1,13]. This study aimed to describe *C. difficile* testing practices and the epidemiology of CDI over a 4-year period at three academic hospitals based in the most populous provinces of South Africa: Gauteng, Western Cape and KwaZulu Natal.

2. Methods

2.1. Study design and setting

This retrospective record review was performed at three hospitals: Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) (1080 beds, Gauteng, quaternary), Tygerberg Hospital (TBH) (1384 beds, Western Cape, tertiary) and Inkosi Albert Luthuli Central Academic Hospital (IALCH) (890 beds, KwaZulu Natal, quaternary). The study was conducted on patients admitted between January 1, 2017 and December 31, 2020. Diagnostic stewardship provided at the three hospitals is to consider CDI in patients 2 years and older with the following clinical presentation: (1) inpatients with new-onset diarrhoea, (2) inpatients with diarrhoea on admission and that continues for more than 3 days and for which an alternate aetiology is not found and (3) patients presenting with diarrhoea and having known risk factors for CDI. However, submission of samples for CDI testing is at the discretion of attending clinician. The laboratories reject formed stool samples submitted for CDI testing. Laboratory and demographic data were obtained from the National Health Laboratory Services (NHLS) Corporate Data Warehouse. Patient-days (PD) data were obtained from the hospital administrative departments. Clinical records were reviewed to assess for recurrence in the rCDI cases identified by laboratory testing. Positive tests within two weeks of a previous positive test were regarded as the same CDI episode.

2.2. Laboratory testing

A two-step algorithm has been used for *C. difficile* testing since 2017 at each of the three clinical microbiology laboratories based at the hospitals. Stool samples initially underwent testing with a combination lateral flow glutamate dehydrogenase (GDH)-toxin immunoassay (C. diff Quik Chek, Techlab, Virginia, USA). Samples that tested GDH negative and toxin negative were reported as negative, and samples that tested GDH positive and toxin positive were reported as positive. Samples that were GDH positive and toxin negative were subsequently tested with the Xpert *C. difficile* assay (Cepheid, California, USA). The Xpert result (positive or negative) was reported as the final result.

An exception to the above testing algorithm occurred at TBH from 1 January to June 30, 2017. During this period, all samples were tested only with the Xpert *C. difficile* assay.

2.3. Data analysis

Demographic data, namely patient age, sex and ward of admission, were collected and analysed. Patients under 2 years of age were excluded from the analysis.

Test positivity rates refer to the proportion of tests performed that were positive. Recurrent CDI rates were expressed as the number of patients with at least one rCDI episode as a proportion of the total number of initial CDI cases for that period. Testing and infection rates were reported per 10 000 PD.

Recurrent CDI was defined as positive *C. difficile* results on laboratory testing WITH new onset of symptoms including diarrhoea (documented in clinical records) between 2 and 8 weeks after the onset of symptoms from the previous CDI episode. In cases where diarrhoea was not documented or medical records were not available to confirm the presence of diarrhoea, these episodes were excluded.

2.4. Statistical analysis

Descriptive statistical analysis was performed using Microsoft Excel. Continuous numerical variables were summarised using medians and interquartile ranges for data not normally distributed. Categorical variables were summarised using proportions and 95 % confidence intervals (CI) were generated. The two-sample Z-test was used to compare categorical variables (Epitools). A two-tailed p-value of <0.05 was considered statistically significant.

2.5. Ethical considerations

A waiver of informed consent was granted for this retrospective study involving results already generated and applied in routine patient care (CMJAH: University of the Witwatersrand M210529; May 31, 2021, TBH: Stellenbosch University N21/06/051; July 15, 2021 and IALCH BREC/00003845/2022); March 3, 2022. Approval was granted from hospital management at each hospital.

3. Results

3.1. Total CDI

Primary CDI rates fluctuated during the period of study, as summarised in Fig. 1. Primary CDI rates at CMJAH were 3.0- and 15.9-fold higher than those at TBH and IALCH, respectively. All three centres had an increase in primary CDI rates in 2020 compared to 2019. This did not surpass the 2017 estimate at TBH.

Demographic data for patients with CDI are outlined by facility in Table 1. Overall, patients with primary CDI had a median age of 39 years (IQR 22–45). This varied by centre: 38 years (IQR 26–52 years), 42 years (IQR 29–56 years) and 31 years (IQR 18–44 years) for CMJAH, TBH and IALCH, respectively. Most patients were from the adult medical wards, with the intensive care units well represented despite their limited bed capacity.

Laboratory testing.

A total of 4712, 2449 and 275 tests were performed at CMJAH, TBH and IALCH respectively, over the four-year study period, equating to median testing rates of 39, 14 and 4 per 10 000 PD respectively. The yearly testing rates are shown in Fig. 2. *C. difficile* testing rates at CMJAH were 2.7- and 10.4-fold higher than those at TBH and IALCH, respectively.

The test positivity rates over the four years were 15 % (95 % CI 14–16), 12 % (95 % CI 11–14) and 8 % (95 % CI 2–11) for CMJAH, TBH and IALCH, respectively, and were significantly higher at CMJAH ($p < 0.001$). The yearly positivity proportions are shown in Fig. 2. This was significantly higher in 2020 compared with the base year of 2017 at CMJAH ($p = 0.013$), but did not differ significantly at the other two facilities.

3.2. Recurrent CDI

In this cohort, 25 patients were identified with rCDI. Table 2 summarizes the rCDI episodes and rates. Three of the 25 patients had two rCDI episodes. The overall rCDI rate per centre ranged from 2 to 5 per 100 incident episodes. The combined rCDI rate for all three centres was




Fig. 1. Primary *C. difficile* infection rates (IR) and median per 10 000 patient days by hospital, 2017–2020. CMJAH: Charlotte Maxeke Johannesburg Academic Hospital; TBH: Tygerberg Hospital; IALCH: Inkosi Albert Luthuli Central Hospital.

Table 1
Pooled 2017–2020 demographics for patients with *C. difficile* infection per hospital.

	CMJAH N = 696 (%)	TBH N = 301 (%)	IALCH N = 23 (%)	Overall N = 1020 (%)
Sex				
Male	350 (50) (95 % CI 47–54)	157 (52) (95 % CI 47–58)	16 (70) (95 % CI 49–84)	523 (51) (95 % CI 48–54)
Age in years				
2–18	80 (11)	26 (9.64)	1 (4)	107 (11)
≥18-<45	352 (51)	155 (51)	15 (65)	522 (51)
≥45-<65	185 (27)	85 (28)	5 (22)	275 (27)
≥65	79 (11)	35 (12)	2 (9)	116 (11)
[a]Ward type				
Adult Surgical	153 (22)	78 (26)	4 (17)	235 (23)
Adult Medical	412 (59)	133 (45)	8 (35)	553 (54)
Adult ICU	114 (16)	60 (20)	10 (44)	184 (18)
Obstetrics and Gynaecology	4 (1)	7 (3)	1 (4)	12 (1)
Paediatric Surgical	13 (2)	2 (1)	0 (0)	15 (2)
Paediatric Emergency Centre		15 (5)		15 (2)

CMJAH: Charlotte Maxeke Johannesburg Academic Hospital; TBH: Tygerberg Hospital; IALCH: Inkosi Albert Luthuli Central Hospital.
[a] Ward type was not stated for 6 adult patients at TBH.

3 per 100 incident episodes.

4. Discussion

This multicentre study of CDI found large differences in infection and testing rates at tertiary/quaternary hospitals located in three different provinces in South Africa. *C. difficile* testing rates and positivity proportions in Gauteng were higher than those in the Western Cape and KwaZulu Natal. This mirrors previously published national data, although the use of different denominators impairs direct comparison [4]. The CDI rate at IALCH was unexpectedly low for a quaternary facility. Possible reasons for the inter-hospital variation include differences in the types of specialist services being offered, differences in antimicrobial prescribing practices, at least somewhat influenced by differences in resistance epidemiology [15], and variable infection prevention and control (IPC) practices. Differences in the prevalent *C. difficile* strains may also have played a role [6].

The median primary CDI rates in this study were lower than the incidence of 8.5 per 10 000 PD reported for developing countries (Africa-Middle East, Latin America, China and developing Asia) from 2000 to 2017 [7]. A recently published systematic review of the burden of CDI in the USA, Canada, Europe and Asia-Pacific regions showed an incidence of 4.00 per 10 000 PD [1], but rates varied widely in the individual countries from the regions. Hospital-acquired CDI rates in the USA and Scotland were 8.00 and 1.99/10 000 PD, respectively. We could not differentiate between hospital-acquired and community-acquired disease for patients with primary CDI in this study.

The higher primary CDI rate seen at TBH in 2017 compared to may have been influenced by undetected outbreaks. The primary CDI rate at IALCH increased substantially in 2018, although the absolute number of cases were small.

Intra-hospital variation in testing rates occurred over time, and the positivity proportion of primary CDI increased at CMJAH in 2020, coinciding with the SARS-CoV-2 pandemic [16]. Additionally, in 2020, the three centres had an increase in primary CDI rates compared to the 2019 rates. The three centres are based in the provinces that had the highest numbers of Covid-19- related admissions in South Africa in 2020 [16]. The increased CDI rates may be due to the increase in antimicrobial use during the pandemic [17,18], or a prioritisation of IPC resources on patients known to be SARS-CoV2-infected at the expense of other pathogens [19]. The usual antimicrobial stewardship (AMS) activities at the three hospitals were negatively impacted by the pandemic [17]. Interestingly, our study was not consistent with findings suggesting reduced CDI rates during the pandemic due to heightened IPC protocols [19].

In this cohort, patients with primary CDI were relatively young, in keeping with SA's population structure [20]. This also aligns with advanced age not being commonly identified as a risk factor for CDI in other African studies [6]. However, data on the overall demographics of




Fig. 2. *C. difficile* positivity proportion (PP) and testing rates (TR) per 10 000 patient days by hospital, 2017–2020. CMJAH: Charlotte Maxeke Johannesburg Academic Hospital; TBH: Tygerberg Hospital; IALCH: Inkosi Albert Luthuli Central Hospital.

Table 2
Recurrent *C. difficile* infection number of episodes and rates.

	Year	No. Of patients with rCDI	No. with 1 rCDI episode	No. with 2 rCDI episodes	rCDI rate (%)
CMJAH	2017	5	5	0	3
	2018	2	1	1	1
	2019	4	3	1	3
	2020	2	2	0	1
	Total	13	11	2	2
TBH	2017	5	5	0	6
	2018	2	1	1	3
	2019	1	1	0	2
	2020	3	3	0	4
	Total	11	10	1	4
IALCH	2017	1	1	0	33
	2018	0	0	0	0
	2019	0	0	0	0
	2020	0	0	0	0
	Total	1	1	0	5

rCDI: Recurrent *C. difficile* infection; CMJAH: Charlotte Maxeke Johannesburg Academic Hospital; TBH: Tygerberg Hospital; IALCH: Inkosi Albert Luthuli Central Hospital.

patients at the three centres was not accessible to allow for comparisons. Whilst advanced age is well established independent risk factor for CDI in other settings, CDI can affect younger populations with specific comorbidities such as chronic kidney disease and inflammatory bowel disease [10]. TB and HIV are other potential comorbidities that may have contributed to the CDI incidence in younger patients. The burden of TB and HIV in SA is significant, particularly among young and middle-aged adults [21,22]. Legenza et al. identified TB as a risk factor for CDI in their retrospective review of CDI epidemiology at district hospitals in Cape Town (in the Western Cape) [2]. As expected, adults comprised the majority of CDI cases in our study, with patients in ICU settings contributing notably [23]. Our retrospective review is limited by not having access to TB and HIV results in the cohort with primary CDI. This should be specifically explored in future research.

This study identified rCDI by combining laboratory testing results with clinical record review for symptoms. Rates of rCDI were low overall, ranging from 2 to 5 per 100 incident cases, in keeping with previous data from SA [4]. The global rCDI rate has been estimated at 10–20 % (median 17 %) with marked differences between regions [1], although there is a striking lack of data from Africa. Rates of rCDI vary from 9.1 % (Asia Pacific region) [24] to 20.8 % (southern Brazil) [25] and 23.7 % (Canada) [1,24,25]. In the United States, it is suggested that up to 35 % of index cases will recur [11] and that this number is on the increase, necessitating continued monitoring to detect trends. Possible explanations for the low rate of rCDI in our setting include inadequate awareness and testing, recurrent infections occurring more than 8 weeks after the initial episode, recurrent symptoms for which patients sought medical care at another institution, and a lack of mortality data for all primary CDI cases. The presence of different strain types in the local setting may also have played a role.

Only three of the 25 patients with rCDI had a second episode of recurrence in our study (12 %), in contrast with a previous estimate of up to 60 % [11]. The rates for multiply recurrent CDI and reasons for potentially lower rates require further investigation in the South African population.

The strengths of this study include the inclusion of hospitals from three provinces in the country and the use of standardized testing algorithms for most of the study period. Longitudinal data allowed for tracking of changes in CDI rates and rCDI was specifically assessed. Limitations of the study include the inability to distinguish between healthcare-associated and community-associated CDI and incomplete data due to missing medical records, The absence of hospital-specific antibiotic consumption and *C. difficile* strain type data limited investigation of possible associations with CDI rates. Differences in the types of specialist services and patient populations, and IPC and AMS practices across the three hospitals, could not be controlled for.

This study found vast differences in *C. difficile* testing and CDI rates. From a diagnostic stewardship perspective, increasing clinician awareness of the risk factors for CDI and indications for CDI testing is important. In addition, promoting awareness of the current CDI treatment guidelines is required. The study findings also support the recommendation that all hospitals should perform surveillance for healthcare facility-onset CDI [26], and it is crucial to continue this practice post SARS-CoV-2-pandemic to understand trends and intervene where appropriate. Baseline data for hospitals is much needed and will

allow benchmarking with other hospitals providing similar care. Prevention of CDI requires attention to IPC measures aiming to prevent exposure to spores and AMS to reduce the risk of *C. difficile*-associated disease in patients colonized with *C. difficile*. CDI rates can be incorporated into hospital AMS quality indicators. There is a need for tracking of rCDI rates, investigation of risk factors, and generation of isolates to facilitate strain typing, in SA and the rest of Africa.

CRediT authorship contribution statement

Trusha Nana: Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis, Conceptualization. **Praksha Ramjathan:** Writing – review & editing, Investigation, Formal analysis. **Khine Swe-Swe Han:** Writing – review & editing, Methodology. **Kessendri Reddy:** Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability

Data will me made available upon request

References

[1] E. Finn, F.L. Andersson, M. Madin-Warburton, Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI, BMC Infect. Dis. 21 (1) (Dec. 2021) 456, https://doi.org/10.1186/s12879-021-06147-y.

[2] L. Legenza, S. Barnett, W. Rose, M. Bianchini, N. Safdar, R. Coetzee, Epidemiology and outcomes of *Clostridium difficile* infection among hospitalised patients: results of a multicentre retrospective study in South Africa, BMJ Glob. Health 3 (4) (Jul. 2018) e000889, https://doi.org/10.1136/bmjgh-2018-000889.

[3] N.M. Rajabally, M. Pentecost, G. Pretorius, A. Whitelaw, M. Mendelson, G. Watermeyer, The Clostridium difficile problem: a South African tertiary institution's prospective perspective, S. Afr. Med. J. 103 (3) (Jan. 2013) 168, https://doi.org/10.7196/SAMJ.6012.

[4] P. de Jager, O. Smith, S. Bolon, J. Thomas, G.A. Richards, Epidemiology of Clostridioides difficile in South Africa, PLoS One 16 (11) (Nov. 2021) e0259771, https://doi.org/10.1371/journal.pone.0259771.

[5] National Department of Health, South Africa, Surveillance for antimicrobial resistance and consumption of antibiotics in South Africa 2018-2022 [Online]. Available: https://knowledgehub.health.gov.za/system/files/elibdownloads/2024-05/South%20African%20AMR%20Surveillance%20Report%202022_FINAL.pdf, Mar. 2024.

[6] B. Kullin, V.R. Abratt, S.J. Reid, T.V. Riley, Clostridioides difficile infection in Africa: a narrative review, Anaerobe 74 (Apr. 2022) 102549, https://doi.org/10.1016/j.anaerobe.2022.102549.

[7] D. Curcio, A. Cané, F.A. Fernández, J. Correa, Clostridium difficile-associated diarrhea in developing countries: a systematic review and meta-analysis, Infect. Dis. Ther. 8 (1) (Mar. 2019) 87–103, https://doi.org/10.1007/s40121-019-0231-8.

[8] G.A. Roldan, A.X. Cui, N.R. Pollock, Assessing the burden of Clostridium difficile infection in low- and middle-income countries, J. Clin. Microbiol. 56 (3) (Mar. 2018) e01747, https://doi.org/10.1128/JCM.01747-17, 17.

[9] L. Legenza, et al., Clostridium difficile infection perceptions and practices: a multicenter qualitative study in South Africa, Antimicrob. Resist. Infect. Control 7 (1) (Dec. 2018) 125, https://doi.org/10.1186/s13756-018-0425-y.

[10] J. Eeuwijk, G. Ferreira, J.P. Yarzabal, M. Robert-Du Ry Van Beest Holle, A systematic literature review on risk factors for and timing of Clostridioides difficile infection in the United States, Infect. Dis. Ther. 13 (2) (Feb. 2024) 273–298, https://doi.org/10.1007/s40121-024-00919-0.

[11] P. Feuerstadt, N. Theriault, G. Tillotson, The burden of CDI in the United States: a multifactorial challenge, BMC Infect. Dis. 23 (1) (Mar. 2023) 132, https://doi.org/10.1186/s12879-023-08096-0.

[12] A. Gupta, A.N. Ananthakrishnan, Economic burden and cost-effectiveness of therapies for *Clostridiodes difficile* infection: a narrative review, Therap Adv Gastroenterol 14 (Jan. 2021) 17562848211018654, https://doi.org/10.1177/17562848211018654.

[13] C. Liu, T. Monaghan, A. Yadegar, T. Louie, D. Kao, Insights into the evolving epidemiology of Clostridioides difficile infection and treatment: a global perspective, Antibiotics 12 (7) (Jul. 2023) 1141, https://doi.org/10.3390/antibiotics12071141.

[14] B. Elliott, G.O. Androga, D.R. Knight, T.V. Riley, Clostridium difficile infection: evolution, phylogeny and molecular epidemiology, Infect. Genet. Evol. 49 (Apr. 2017) 1–11, https://doi.org/10.1016/j.meegid.2016.12.018.

[15] O. Perovic, H. Ismail, E.V. Schalkwyk, Antimicrobial resistance surveillance in the South African public sector, Southern African Journal of Infectious Diseases 33 (4) (Oct. 2018) 118–129, https://doi.org/10.1080/23120053.2018.1469851.

[16] National Institute of Communicable Diseases, COVID-19 weekly epidemiology brief, South Africa. Week 53 2020, https://www.nicd.ac.za/wp-content/uploads/2021/01/NICD-COVID-19-Weekly-Sentinel-Hospital-Surveillnace-update-Week-53.pdf, 2021. (Accessed 23 June 2024).

[17] V. Chibabhai, G.A. Richards, O. Perovic, A.G. Duse, Collateral damage of the covid-19 pandemic: exacerbation of antimicrobial resistance and disruptions to antimicrobial stewardship programmes? S. Afr. Med. J. 110 (7) (Jun. 2020) https://doi.org/10.7196/SAMJ.2020.v110i7.14917.

[18] A. Sandhu, et al., *Clostridioides difficile* in COVID-19 patients, Detroit, Michigan, USA, march–april 2020, Emerg. Infect. Dis. 26 (9) (Sep. 2020) 2272–2274, https://doi.org/10.3201/eid2609.202126.

[19] K.B. Choi, et al., Trends in *Clostridioides difficile* infection rates in Canadian hospitals during the coronavirus disease 2019 (COVID-19) pandemic, Infect. Control Hosp. Epidemiol. 44 (7) (Jul. 2023) 1180–1183, https://doi.org/10.1017/ice.2022.210.

[20] Statistics South Africa, "SA population reaches 58.8 million." Accessed: June. 23, 2024. [Online]. Available: https://www.statssa.gov.za/?p=12362.

[21] The First National TB Prevalence Survey South Africa 2018." National Department of Health. [Online]. Available: https://knowledgehub.health.gov.za/elibrary/first-national-tb-prevalence-survey-south-africa-2018.

[22] K. Zuma, et al., The HIV epidemic in South Africa: key findings from 2017 national population-based survey, IJERPH 19 (13) (Jul. 2022) 8125, https://doi.org/10.3390/ijerph19138125.

[23] S. Karanika, S. Paudel, F.N. Zervou, C. Grigoras, I.M. Zacharioudakis, E. Mylonakis, Prevalence and clinical outcomes of Clostridium difficile infection in the intensive care unit: a systematic review and meta-analysis, Open Forum Infect. Dis. 3 (1) (Jan. 2016) ofv186, https://doi.org/10.1093/ofid/ofv186.

[24] D.A. Collins, et al., *Clostridioides difficile* infection in the Asia-Pacific region, Emerg. Microb. Infect. 9 (1) (Jan. 2020) 42–52, https://doi.org/10.1080/22221751.2019.1702480.

[25] A.C. Maestri, et al., Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil, Anaerobe 64 (Aug. 2020) 102238, https://doi.org/10.1016/j.anaerobe.2020.102238.

[26] T. Nana, et al., South African Society of Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection prevention and control guideline, Southern African Journal of Infectious Diseases 35 (1) (Oct. 2020), https://doi.org/10.4102/sajid.v35i1.219.